So here's the thing about Eli Lilly right now — Wall Street has completely fallen in love with it, and I get why. The GLP-1 craze is real, and Mounjaro and Zepbound are absolutely crushing it in the market. These two drugs alone are pulling in 56% of the company's revenue, with growth rates hitting 99% and 175% respectively for 2025. That's genuinely impressive.

But here's where I pump the brakes. When a stock gets this much love, the valuation gets... let's just say aggressive. Eli Lilly is trading at a P/E ratio of 44 right now. And the dividend yield? A measly 0.6%. That's not a yield, that's basically nothing. The market is pricing this company like it's going to execute perfectly forever, which is a dangerous game.

The real issue is concentration risk. Eli Lilly has way too much riding on two drugs. If something goes sideways with either of them, the stock gets hit hard. Wall Street seems to be ignoring that completely.

Now, if you're actually looking for a pharmaceutical play with real income, Merck is worth grabbing with both hands. I know it's not as sexy as the GLP-1 story — Merck focuses on cancer, infections, and cardiometabolic disease. Boring stuff compared to weight loss drugs, right? But here's the kicker: these are massive therapeutic categories that aren't going anywhere.

Merck's valuation is way more reasonable at a P/E of 16. And the yield? 2.8%. That's nearly five times higher than Eli Lilly. Plus, Merck has this solid track record of supporting its dividend over three decades. The payout ratio sits around 50%, which means there's room to keep growing that dividend without any real risk of a cut.

There's also the Keytruda situation. Yeah, there's a patent expiration coming in the U.S., but Merck has international patents extending into the early 2030s. They're also working on a new delivery method that could push protection into the late 2030s. The story isn't as dire as people think.

Look, Eli Lilly isn't a bad company. The fundamentals are solid. But the valuation has gotten completely out of hand. If you want exposure to big pharma with actual dividend income, Merck gives you better value and better yield without the concentration risk. Sometimes boring is exactly what your portfolio needs.